Tuberculosis (TB) remains a major public health problem internationally, causing 9.6 million
new cases and 1.5 million deaths worldwide in 2014. The Bacillus Calmette-Guérin vaccine
is the only licensed vaccine against TB, but its protective effect does not extend to controlling
the development of infectious pulmonary disease in adults. The development of a more
effective vaccine against TB is therefore a pressing need for global health. Although it is
established that cell-mediated immunity is necessary for the control of latent infection, the …